ClinicalTrials.gg
Active, not recruitingNCT04643379Updated Oct 27, 2026Results posted

Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma

A Phase 2 interventional study of Olaparib and Pembrolizumab in Recurrent Head and Neck Squamous Cell Carcinoma and Metastatic Head and Neck Squamous Cell Carcinoma, sponsored by Washington University School of Medicine. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Washington University School of Medicine · Phase 2, Interventional, and Treatment

How we know · 7 judgments

Updated Oct 27, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies in Squamous Cell Carcinoma of Head and Neck by Washington University School of Medicine — 6 open to participants now, 12 under way, 1 of them phase 3. Squamous Cell Carcinoma of Head and Neck · Washington University School of Medicine.

Enrollment
17th of 23
30 · median 43
Started
2021
with 3 others
Phase 2
16 of 24
4 open now
Primary completion
2025-10
later than 1 of 11 live
Registered
15th of 24
by date

Among the 24 studies in Squamous Cell Carcinoma of Head and Neck by Washington University School of Medicine, this one is the 17th largest by enrollment of the 23 interventional ones that give a count, is one of 4 that started in 2021, is one of 16 in phase 2, reaches primary completion later than 1 of the 11 other live ones, and was the 15th registered.

Squamous Cell Carcinoma of Head and Neck

2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

6 of the 24 studies in Squamous Cell Carcinoma of Head and Neck by Washington University School of Medicine are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Squamous Cell Carcinoma of Head and Neck by Washington University School of Medicine, or all of them as a file.
02

Study summary

In this study, patients with recurrent or metastatic head and neck squamous cell carcinoma will receive first line treatment with olaparib, pembrolizumab, and carboplatin. The primary hypothesis is that olaparib, pembrolizumab and carboplatin will result in an overall response rate (ORR) higher than the historical ORR observed with pembrolizumab, platinum and 5-FU.

03

Conditions studied

  • Recurrent Head and Neck Squamous Cell Carcinoma
  • Metastatic Head and Neck Squamous Cell Carcinoma
04

Who can participate

The criteria were revised on the registry on Oct 27, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of or cytologically confirmed recurrent or HNSCC of the oral cavity, oropharynx, larynx, hypopharynx, or p16+ SCC of the neck (unknown primary).
  • per . Measurable disease defined as lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as ≥ 10 mm with CT scan, as ≥ 20 mm by chest x-ray, or ≥ 10 mm with calipers by clinical exam.
  • Incurable disease, or ineligible for (including patient declined) local therapy.
  • At least 18 years of age.
  • performance status ≤ 1
  • ≥ 16 weeks.
  • Normal bone marrow and organ function as defined below (specimens must be collected within 10 days prior to the start of study treatment):

    • ≥ 10.0 g/dL (criteria must be met without erythropoietin dependency and without packed red blood cell transfusion within the last 2 weeks)
    • ≥ 1,500/mcL
    • ≥ 100,000/mcL
    • or PT ≤ 1.5 x institutional (IULN) and aPTT ≤ 1.5 x IULN unless participant is receiving anticoagulant therapy as long as PT or aPTT is within therapeutic range of intended use of anticoagulants
    • Total ≤ 1.5 x IULN
    • (SGOT)/ALT(SGPT) ≤ 2.5 x IULN unless liver metastases are present (in which case they must be ≤ 5 x IULN)
    • Serum creatinine \<1.5 x ULN or ≥ 51 mL/min by Cockcroft-Gault or based on a 24-hour urine test
  • Known p16 expression, if oropharyngeal primary.
  • or evidence of non-childbearing status for women of : negative urine or serum pregnancy test within 72 hours of Day 1 of study treatment:

    *Postmenopausal is defined as:

    • Amenorrheic for 1 year or more following cessation of exogenous hormonal treatments
    • Luteinizing hormone (LH) and Follicle stimulating hormone (FSH) levels in the post menopausal range for women under 50
    • radiation-induced oophorectomy with last menses >1 year ago
    • chemotherapy-induced menopause with >1 year interval since last menses
    • surgical sterilization (bilateral oophorectomy or hysterectomy)
  • Male patients must use a condom during treatment and for 3 months after the last dose of olaparib when having sexual intercourse with a pregnant woman or with a woman of childbearing potential. Female partners of male patients should also use a highly effective form of (see Section 5.6) if they are of childbearing potential
  • Ability to understand and willingness to sign an IRB approved written document (or that of legally authorized representative, if applicable).

Exclusion criteria

Exclusion Criteria:

  • Progression within 6 months of curatively intended systemic therapy given for locoregionally advanced disease.
  • therapy within 28 days of treatment start.
  • Prior systemic therapy for recurrent or disease.
  • Known / metastatic disease.
  • Other unless curatively treated with no evidence of disease for ≥ 2 years except: adequately treated non-melanoma skin cancer, curative treated in situ cancer of the cervix, ductal carcinoma in situ (DCIS), stage 1 grade 1 endometrial carcinoma; or low risk-disease per discretion of the PI.
  • A history of allergic reactions attributed to compounds of similar chemical or biologic composition to olaparib, pembrolizumab, carboplatin, or other agents used in the study.
  • Has received prior therapy with an , anti-PD-L1, or anti PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX 40, CD137).
  • Has received prior radiotherapy within 2 weeks of start of study intervention. Participants must have recovered from all radiation-related toxicities, not require , and not have had radiation pneumonitis. A 1-week is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease.
  • Concomitant use of known strong inhibitors (e.g., itraconazole, telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) or moderate CYP3A inhibitors (e.g., ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil). The required washout period prior to starting olaparib is 2 weeks.
  • Concomitant use of known strong CYP3A inducers (e.g. phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine, and St. John's wort) or moderate CYP3A inducers (e.g., bosentan, efavirenz, modafinil). The required washout period prior to starting olaparib is 5 weeks for enzalutamide or phenobarbital and 3 weeks for other agents.
  • Resting indicating uncontrolled, potentially reversible cardiac conditions as judged by the investigator (e.g., unstable ischemia, uncontrolled symptomatic arrhythmia, congestive heart failure, prolongation > 500 ms, electrolyte disturbances, etc.) or patients with congenital long QT syndrome.
  • Diagnosis of myelodysplastic syndrome/acute myeloid leukemia or with features suggestive of MDS/AML.
  • Major surgery within 2 weeks of starting study treatment; must have recovered from any effects of major surgery.
  • Has a diagnosis of immunodeficiency or is receiving chronic systemic corticosteroid therapy (in doses exceeding 10 mg daily of prednisone equivalent) or any other form of therapy within 7 days prior to the first dose of treatment.
  • Received a or live-attenuated vaccine within 30 days prior to the first dose of pembrolizumab. Administration of killed vaccines is allowed. Examples of live vaccines is allowed. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g. FluMist®) are live attenuated vaccines and are not allowed.
  • Considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease, or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, extensive interstitial bilateral lung disease on high resolution computed tomography (HRCT) scan or any psychiatric disorder that prohibits obtaining .
  • Unable to swallow orally administered medication or with gastrointestinal disorder likely to interfere with absorption of study medication.
  • Pregnant and/or breastfeeding. A who has a positive urine pregnancy test within 72 hours of first dose of treatment. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.

Female patients who are expecting to conceive or male patients who are expecting to father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of trial treatment.

  • Prior organ or stem cell transplant or double umbilical cord blood transplantation.
  • Has an active disease (i.e. rheumatoid arthritis, lupus, Sjogren's syndrome) that has required IV or subcutaneous systemic treatment in the past 2 years (excluding Rituxan). Replacement therapy (i.e. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
  • Has a known history of (defined as Hepatitis B surface antigen [HBsAg] reactive) or known active virus (defined as HCV RNA [qualitative] is detected) infection. Note: no testing for Hepatitis B and Hepatitis C is required unless mandated by local health authority.
  • History of (non-infectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.
  • Has a known history of active TB (Bacillus Tuberculosis).
Terms in these criteria, in plain language(34)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Olaparib + Pembrolizumab + Carboplatin AUC

    -Patients enrolled in this study will receive olaparib, pembrolizumab and carboplatin in three-week cycles for six cycles, followed by maintenance therapy with three-week cycles of olaparib and pembrolizumab. Treatment will continue until disease progression, intolerable toxicity, patient or physician decision to stop therapy, or after 35 cycles, whichever occurs first. Drug dosing for each cycle is as follows: * Olaparib 200 mg twice per day (bid) by mouth (po) Days 1-10 for the first six cycles (when given with carboplatin), followed by 400 mg bid po Days 1-21 of subsequent cycles. * Pembrolizumab 200 mg intravenous (IV) Day 1. * Carboplatin AUC 5 IV on Day 1 for up to six cycles.

    Drug: Olaparib · Drug: Pembrolizumab · Drug: Carboplatin · Procedure: Peripheral blood draw

Interventions

  • Supplied by Merck \& Co.

    Also known as: Lynparza

  • Supplied by Merck \& Co.

    Also known as: Keytruda

  • Commercially available

  • ProcedurePeripheral blood draw

    Baseline (cycle 1 day 1), cycle 2 day 1, and at disease progression

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) as Assessed by RECIST v1.1

    ORR is defined as the number of participants with complete response (CR) or partial response (PR) per RECIST v1.1. CR is defined as disappearance of target and non-target lesions and normalization of tumor markers. Pathological lymph nodes must have short axis measures \<10 mm. PR is defined as at least a 30% decrease in the sum of measures (longest diameter for tumor lesions and short axis measure for nodes) of target lesions, taking as reference the baseline sum of diameters. Non-target lesions must be non-PD.

    Time frame: Through completion of follow-up (median length of follow-up 24.8 months, IQR=7.0-36.8 months)

Secondary outcomes

  1. Duration of Response (DoR)

    DoR is defined as time from date of first response (complete or partial) on CT scans through date of progression or last date of follow-up alive, whichever comes first. Complete response (CR) is defined as disappearance of target and non-target lesions and normalization of tumor markers. Pathological lymph nodes must have short axis measures \<10 mm. Partial response (PR) is defined as at least a 30% decrease in the sum of measures (longest diameter for tumor lesions and short axis measure for nodes) of target lesions, taking as reference the baseline sum of diameters. Non-target lesions must be non-PD.

    Time frame: Through completion of follow-up (median length of follow-up 33.8 months, IQR=20.5-41.8 months)

  2. Incidence of Adverse Events

    Grade 1 to 2 adverse events with an incidence of ≥10% are shown. All grade 3 to 5 events are shown.

    Time frame: Through 28 days after completion of treatment (median cycles (each cycle is 21 days) of treatment=10, IQR=3-26 cycles)

  3. Correlation of Baseline Tumor HR and PTEN Gene Status With Objective Response Rate (ORR)

    Noted as altered (defined as presence of an alteration in one or more HR genes or PTEN) or not altered. ORR is defined as the number of participants with complete response (CR) or partial response (PR) per RECIST v1.1. CR is defined as disappearance of target and non-target lesions and normalization of tumor markers. Pathological lymph nodes must have short axis measures \<10 mm. PR is defined as at least a 30% decrease in the sum of measures (longest diameter for tumor lesions and short axis measure for nodes) of target lesions, taking as reference the baseline sum of diameters. Non-target lesions must be non-PD.

    Time frame: Through completion of follow-up (median length of follow-up 24.8 months, IQR=7.0-36.8 months)

  4. Correlation of Baseline Tumor PD-L1 CPS Status With Objective Response Rate (ORR)

    PD-L1 CPS status includes ≥20 or CPS 0-19. ORR is defined as the number of participants with complete response (CR) or partial response (PR) per RECIST v1.1. CR is defined as disappearance of target and non-target lesions and normalization of tumor markers. Pathological lymph nodes must have short axis measures \<10 mm. PR is defined as at least a 30% decrease in the sum of measures (longest diameter for tumor lesions and short axis measure for nodes) of target lesions, taking as reference the baseline sum of diameters. Non-target lesions must be non-PD.

    Time frame: Through completion of follow-up (median length of follow-up 24.8 months, IQR=7.0-36.8 months)

  5. Correlation of Baseline Tumor HPV (p16) Expression Status With Objective Response Rate (ORR)

    Noted as HPV positive or HPV negative. ORR is defined as the number of participants with complete response (CR) or partial response (PR) per RECIST v1.1. CR is defined as disappearance of target and non-target lesions and normalization of tumor markers. Pathological lymph nodes must have short axis measures \<10 mm. PR is defined as at least a 30% decrease in the sum of measures (longest diameter for tumor lesions and short axis measure for nodes) of target lesions, taking as reference the baseline sum of diameters. Non-target lesions must be non-PD.

    Time frame: Through completion of follow-up (median length of follow-up 24.8 months, IQR=7.0-36.8 months)

  6. Correlation of Baseline Tumor HR and PTEN Gene Status With Median Progression Free Survival (PFS)

    Noted as altered (defined as presence of an alteration in one or more HR genes or PTEN) or not altered. PFS is defined as time from study enrollment until the date of progression or death, whichever occurs first.

    Time frame: Through completion of follow-up (median length of follow-up 24.8 months, IQR=7.0-36.8 months)

  7. Correlation of Baseline Tumor PD-L1 CPS Status With Median Progression-free Survival (PFS)

    PD-L1 CPS status includes ≥20 or CPS 0-19. PFS is defined as time from study enrollment until the date of progression or death, whichever occurs first.

    Time frame: Through completion of follow-up (median length of follow-up 24.8 months, IQR=7.0-36.8 months)

  8. Correlation of Baseline Tumor HPV (p16) Expression Status With Median Progression-free Survival (PFS)

    Noted as HPV positive or HPV negative. PFS is defined as time from study enrollment until the date of progression or death, whichever occurs first.

    Time frame: Through completion of follow-up (median length of follow-up 24.8 months, IQR=7.0-36.8 months)

  9. Correlation of Baseline Tumor HR and PTEN Gene Status With Median Overall Survival (OS)

    Noted as altered (defined as presence of an alteration in one or more HR genes or PTEN) or not altered. OS is defined as the time from the date of first study treatment until death.

    Time frame: Through completion of follow-up (median length of follow-up 24.8 months, IQR=7.0-36.8 months)

  10. Correlation of Baseline Tumor PD-L1 CPS Status With Median Overall Survival (OS)

    PD-L1 CPS status includes ≥20 or CPS 0-19. OS is defined as the time from the date of first study treatment until death.

    Time frame: Through completion of follow-up (median length of follow-up 24.8 months, IQR=7.0-36.8 months)

  11. Correlation of Baseline Tumor HPV (p16) Expression Status With Median Overall Survival (OS)

    Noted as HPV positive or HPV negative. OS is defined as the time from the date of first study treatment until death.

    Time frame: Through completion of follow-up (median length of follow-up 24.8 months, IQR=7.0-36.8 months)

  12. Progression-free Survival (PFS)

    PFS is defined as time from study enrollment until the date of progression or death, whichever occurs first.

    Time frame: Through completion of follow-up (estimated to be 3 years)

  13. Overall Survival (OS)

    OS is defined as the time from the date of first study treatment until death.

    Time frame: Through completion of follow-up (estimated to be 3 years)

07

Results

Posted Oct 27, 2026

Participant flow

Participant flow — Overall Study
MilestoneOlaparib + Pembrolizumab + Carboplatin AUC
Started30
Completed4
Not completed26
Withdrew: Disease progression, relapse during active treatment18
Withdrew: Death4
Withdrew: Patient withdrawal or refusal after beginning protocol therapy2
Withdrew: Physician decision1
Withdrew: Original biopsy showed scc further testing showed acc1

Outcome measures

PrimaryObjective Response Rate (ORR) as Assessed by RECIST v1.1

ORR is defined as the number of participants with complete response (CR) or partial response (PR) per RECIST v1.1. CR is defined as disappearance of target and non-target lesions and normalization of tumor markers. Pathological lymph nodes must have short axis measures \<10 mm. PR is defined as at least a 30% decrease in the sum of measures (longest diameter for tumor lesions and short axis measure for nodes) of target lesions, taking as reference the baseline sum of diameters. Non-target lesions must be non-PD.

Time frame:
Through completion of follow-up (median length of follow-up 24.8 months, IQR=7.0-36.8 months)
Reported as:
Number · percentage of participants
Objective Response Rate (ORR) as Assessed by RECIST v1.1
percentage of participantsOlaparib + Pembrolizumab + Carboplatin AUC
Objective Response Rate (ORR) as Assessed by RECIST v1.151.7 (35.2 to 68.0)
SecondaryDuration of Response (DoR)

DoR is defined as time from date of first response (complete or partial) on CT scans through date of progression or last date of follow-up alive, whichever comes first. Complete response (CR) is defined as disappearance of target and non-target lesions and normalization of tumor markers. Pathological lymph nodes must have short axis measures \<10 mm. Partial response (PR) is defined as at least a 30% decrease in the sum of measures (longest diameter for tumor lesions and short axis measure for nodes) of target lesions, taking as reference the baseline sum of diameters. Non-target lesions must be non-PD.

Time frame:
Through completion of follow-up (median length of follow-up 33.8 months, IQR=20.5-41.8 months)
Reported as:
Median · months
Duration of Response (DoR)
monthsOlaparib + Pembrolizumab + Carboplatin AUC
Duration of Response (DoR)17.5 (6.8 to 37.6)
SecondaryIncidence of Adverse Events

Grade 1 to 2 adverse events with an incidence of ≥10% are shown. All grade 3 to 5 events are shown.

Time frame:
Through 28 days after completion of treatment (median cycles (each cycle is 21 days) of treatment=10, IQR=3-26 cycles)
Reported as:
Count of participants · Participants
Incidence of Adverse Events
ParticipantsOlaparib + Pembrolizumab + Carboplatin AUC
Grade 1/2 Abdominal pain3
Grade 3/4/5 Acute kidney injury1
Grade 1/2 Alanine aminotransferase increased5
Grade 3/4/5 Alanine aminotransferase increased3
Grade 1/2 Alkaline phosphatase increased8
Grade 3/4/5 Anaphylaxis1
Grade 1/2 Anemia18
Grade 3/4/5 Anemia8
Grade 1/2 Anorexia10
Grade 3/4/5 Anorexia5
Grade 1/2 Anxiety3
Grade 1/2 Aspartate aminotransferase increased6
Grade 3/4/5 Aspartate aminotransferase increased2
Grade 3/4/5 Atrial flutter1
Grade 3/4/5 Back pain1
Grade 1/2 Blood bilirubin3
Grade 1/2 Bone pain3
Grade 1/2 Chills3
Grade 3/4/5 Confusion1
Grade 1/2 Constipation11
Grade 1/2 Cough5
Grade 1/2 Creatinine10
Grade 3/4/5 Dental caries1
Grade 1/2 Diarrhea8
Grade 3/4/5 Diarrhea1
Grade 1/2 Dizziness8
Grade 1/2 Dry mouth3
Grade 1/2 Dry skin10
Grade 1/2 Dysarthria4
Grade 1/2 Dysgeusia4
Grade 1/2 Dysphagia9
Grade 3/4/5 Dysphagia3
Grade 1/2 Dyspnea8
Grade 3/4/5 Dyspnea2
Grade 1/2 Edema limbs7
Grade 3/4/5 Esophageal fistula1
Grade 1/2 Fatigue23
Grade 3/4/5 Fatigue4
Grade 3/4/5 Fall1
Grade 3/4/5 Febrile neutropenia1
Grade 3/4/5 Fracture1
Grade 1/2 Fever3
Grade 1/2 Headache3
Grade 1/2 Hypercalcemia9
Grade 1/2 Hyperkalemia10
Grade 1/2 Hypertension8
Grade 3/4/5 Hypertension1
Grade 1/2 Hypoalbuminemia10
Grade 1/2 Hypocalcemia6
Grade 1/2 Hypoglycemia5
Grade 1/2 Hypokalemia5
Grade 3/4/5 Hypokalemia2
Grade 1/2 Hyponatremia20
Grade 1/2 Hypophosphatemia3
Grade 1/2 Hypotension4
Grade 3/4/5 Hypotension1
Grade 1/2 Hypothyroidism5
Grade 3/4/5 Hypoxia1
Grade 3/4/5 Infusion related reaction1
Grade 3/4/5 Laryngeal hemorrhage1
Grade 3/4/5 Lung infection1
Grade 3/4/5 Lymphedema1
Grade 1/2 Lymphocyte count decreased5
Grade 3/4/5 Lymphocyte count decreased16
Grade 3/4/5 Mucosal infection1
Grade 1/2 Mucositis oral6
Grade 3/4/5 Mucositis oral1
Grade 3/4/5 Myocardial infarction1
Grade 1/2 Nasal congestion7
Grade 1/2 Nausea13
Grade 3/4/5 Nausea1
Grade 1/2 Neck pain5
Grade 1/2 Neutrophil count decreased5
Grade 3/4/5 Neutrophil count decreased15
Grade 3/4/5 Oral pain1
Grade 3/4/5 Pericarditis1
Grade 1/2 Peripheral sensory neuropathy4
Grade 1/2 Platelet count decreased16
Grade 3/4/5 Platelet count decreased5
Grade 1/2 Productive cough3
Grade 1/2 Rash maculo-papular4
Grade 1/2 Sinus bradycardia4
Grade 1/2 Sinus tachycardia4
Grade 3/4/5 Skin infection1
Grade 3/4/5 Soft tissue infection1
Grade 3/4/5 Stoma site infection1
Grade 3/4/5 Sudden death NOS1
Grade 3/4/5 Syncope3
Grade 3/4/5 Tooth infection1
Grade 1/2 Upper respiratory infection5
Grade 3/4/5 Urinary tract infection1
Grade 1/2 Vomiting9
Grade 1/2 Weight gain4
Grade 1/2 Weight loss4
Grade 3/4/5 Weight loss3
Grade 1/2 White blood cell decreased13
Grade 3/4/5 White blood cell decreased14
SecondaryCorrelation of Baseline Tumor HR and PTEN Gene Status With Objective Response Rate (ORR)

Noted as altered (defined as presence of an alteration in one or more HR genes or PTEN) or not altered. ORR is defined as the number of participants with complete response (CR) or partial response (PR) per RECIST v1.1. CR is defined as disappearance of target and non-target lesions and normalization of tumor markers. Pathological lymph nodes must have short axis measures \<10 mm. PR is defined as at least a 30% decrease in the sum of measures (longest diameter for tumor lesions and short axis measure for nodes) of target lesions, taking as reference the baseline sum of diameters. Non-target lesions must be non-PD.

Time frame:
Through completion of follow-up (median length of follow-up 24.8 months, IQR=7.0-36.8 months)
Reported as:
Count of participants · Participants
Correlation of Baseline Tumor HR and PTEN Gene Status With Objective Response Rate (ORR)
ParticipantsOlaparib + Pembrolizumab + Carboplatin AUC
Altered with objective response of complete or partial response5
Not altered with objective response of complete or partial response10
SecondaryCorrelation of Baseline Tumor PD-L1 CPS Status With Objective Response Rate (ORR)

PD-L1 CPS status includes ≥20 or CPS 0-19. ORR is defined as the number of participants with complete response (CR) or partial response (PR) per RECIST v1.1. CR is defined as disappearance of target and non-target lesions and normalization of tumor markers. Pathological lymph nodes must have short axis measures \<10 mm. PR is defined as at least a 30% decrease in the sum of measures (longest diameter for tumor lesions and short axis measure for nodes) of target lesions, taking as reference the baseline sum of diameters. Non-target lesions must be non-PD.

Time frame:
Through completion of follow-up (median length of follow-up 24.8 months, IQR=7.0-36.8 months)
Reported as:
Count of participants · Participants
Correlation of Baseline Tumor PD-L1 CPS Status With Objective Response Rate (ORR)
ParticipantsOlaparib + Pembrolizumab + Carboplatin AUC
PD-L1 CPS ≥20 with objective response of complete or partial response10
PD-L1 CPS 0-19 with objective response of complete or partial response5
SecondaryCorrelation of Baseline Tumor HPV (p16) Expression Status With Objective Response Rate (ORR)

Noted as HPV positive or HPV negative. ORR is defined as the number of participants with complete response (CR) or partial response (PR) per RECIST v1.1. CR is defined as disappearance of target and non-target lesions and normalization of tumor markers. Pathological lymph nodes must have short axis measures \<10 mm. PR is defined as at least a 30% decrease in the sum of measures (longest diameter for tumor lesions and short axis measure for nodes) of target lesions, taking as reference the baseline sum of diameters. Non-target lesions must be non-PD.

Time frame:
Through completion of follow-up (median length of follow-up 24.8 months, IQR=7.0-36.8 months)
Reported as:
Count of participants · Participants
Correlation of Baseline Tumor HPV (p16) Expression Status With Objective Response Rate (ORR)
ParticipantsOlaparib + Pembrolizumab + Carboplatin AUC
HPV Positive with objective response of complete or partial response8
HPV Negative with objective response of complete or partial response7
SecondaryCorrelation of Baseline Tumor HR and PTEN Gene Status With Median Progression Free Survival (PFS)

Noted as altered (defined as presence of an alteration in one or more HR genes or PTEN) or not altered. PFS is defined as time from study enrollment until the date of progression or death, whichever occurs first.

Time frame:
Through completion of follow-up (median length of follow-up 24.8 months, IQR=7.0-36.8 months)
Reported as:
Number · months
Correlation of Baseline Tumor HR and PTEN Gene Status With Median Progression Free Survival (PFS)
monthsOlaparib + Pembrolizumab + Carboplatin AUC
Altered - median PFS (months)NA (2.3 to NA)
Not Altered - median PFS (months)7.4 (2.6 to 14.5)
SecondaryCorrelation of Baseline Tumor PD-L1 CPS Status With Median Progression-free Survival (PFS)

PD-L1 CPS status includes ≥20 or CPS 0-19. PFS is defined as time from study enrollment until the date of progression or death, whichever occurs first.

Time frame:
Through completion of follow-up (median length of follow-up 24.8 months, IQR=7.0-36.8 months)
Reported as:
Number · months
Correlation of Baseline Tumor PD-L1 CPS Status With Median Progression-free Survival (PFS)
monthsOlaparib + Pembrolizumab + Carboplatin AUC
PD-L1 CPS ≥20 with median PFS (months)10.8 (2.6 to 18.4)
PD-L1 CPS 0-19 with median PFS (months)7.4 (1.4 to 18.2)
SecondaryCorrelation of Baseline Tumor HPV (p16) Expression Status With Median Progression-free Survival (PFS)

Noted as HPV positive or HPV negative. PFS is defined as time from study enrollment until the date of progression or death, whichever occurs first.

Time frame:
Through completion of follow-up (median length of follow-up 24.8 months, IQR=7.0-36.8 months)
Reported as:
Median · months
Correlation of Baseline Tumor HPV (p16) Expression Status With Median Progression-free Survival (PFS)
monthsOlaparib + Pembrolizumab + Carboplatin AUC
HPV Positive with median PFS (months)11.3 (4.1 to 18.4)
HPV Negative with median PFS (months)5.1 (1.6 to NA)
SecondaryCorrelation of Baseline Tumor HR and PTEN Gene Status With Median Overall Survival (OS)

Noted as altered (defined as presence of an alteration in one or more HR genes or PTEN) or not altered. OS is defined as the time from the date of first study treatment until death.

Time frame:
Through completion of follow-up (median length of follow-up 24.8 months, IQR=7.0-36.8 months)
Reported as:
Number · months
Correlation of Baseline Tumor HR and PTEN Gene Status With Median Overall Survival (OS)
monthsOlaparib + Pembrolizumab + Carboplatin AUC
Altered - median OS (months)14.7 (4.4 to NA)
Not Altered - median OS (months)24.5 (7.1 to 24.6)
SecondaryCorrelation of Baseline Tumor PD-L1 CPS Status With Median Overall Survival (OS)

PD-L1 CPS status includes ≥20 or CPS 0-19. OS is defined as the time from the date of first study treatment until death.

Time frame:
Through completion of follow-up (median length of follow-up 24.8 months, IQR=7.0-36.8 months)
Reported as:
Number · months
Correlation of Baseline Tumor PD-L1 CPS Status With Median Overall Survival (OS)
monthsOlaparib + Pembrolizumab + Carboplatin AUC
PD-L1 CPS ≥20 with median OS (months)24.5 (7.1 to NA)
PD-L1 CPS 0-19 with median OS (months)24.6 (4.1 to NA)
SecondaryCorrelation of Baseline Tumor HPV (p16) Expression Status With Median Overall Survival (OS)

Noted as HPV positive or HPV negative. OS is defined as the time from the date of first study treatment until death.

Time frame:
Through completion of follow-up (median length of follow-up 24.8 months, IQR=7.0-36.8 months)
Reported as:
Median · months
Correlation of Baseline Tumor HPV (p16) Expression Status With Median Overall Survival (OS)
monthsOlaparib + Pembrolizumab + Carboplatin AUC
HPV Positive with median OS (months)24.5 (6.9 to NA)
HPV Negative with median OS (months)12.7 (5.6 to NA)
SecondaryProgression-free Survival (PFS)

PFS is defined as time from study enrollment until the date of progression or death, whichever occurs first.

Time frame:
Through completion of follow-up (estimated to be 3 years)

Results for this outcome have not been posted.

SecondaryOverall Survival (OS)

OS is defined as the time from the date of first study treatment until death.

Time frame:
Through completion of follow-up (estimated to be 3 years)

Results for this outcome have not been posted.

Adverse events

Collected over Adverse events were evaluated from start of treatment to 30 days after completion of treatment. Median total time for adverse event collection was 8 months (full range 1 month-28 months). All cause mortality is followed from start of treatment to completion of follow up (up to 3 years).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Olaparib + Pembrolizumab + Carboplatin AUC19/30 (63.3%)12/30 (40%)30/30 (100%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventOlaparib + Pembrolizumab + Carboplatin AUC
AnemiaBlood and lymphatic system disorders1/30
Atrial flutterCardiac disorders1/30
Myocardial infarctionCardiac disorders1/30
PericarditisCardiac disorders1/30
DysphagiaGastrointestinal disorders1/30
Esophageal fistulaGastrointestinal disorders1/30
FatigueGeneral disorders1/30
Sudden death NOSGeneral disorders1/30
AnaphylaxisImmune system disorders1/30
Lung infectionInfections and infestations1/30
Most frequent other events
Showing 10 of 128
Most frequent other events
EventOlaparib + Pembrolizumab + Carboplatin AUC
White blood cell decreasedInvestigations27/30
FatigueGeneral disorders26/30
AnemiaBlood and lymphatic system disorders25/30
Lymphocyte count decreasedInvestigations21/30
Neutrophil count decreasedInvestigations20/30
Platelet count decreasedInvestigations20/30
HyponatremiaMetabolism and nutrition disorders20/30
AnorexiaMetabolism and nutrition disorders15/30
NauseaGastrointestinal disorders14/30
ConstipationGastrointestinal disorders11/30

Baseline characteristics

Age, Continuous
Age, Continuous(years)Olaparib + Pembrolizumab + Carboplatin AUC
Median66 (61 to 70)
Sex: Female, Male
Sex: Female, Male(Participants)Olaparib + Pembrolizumab + Carboplatin AUC
Female6
Male24
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Olaparib + Pembrolizumab + Carboplatin AUC
Hispanic or Latino0
Not Hispanic or Latino30
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Olaparib + Pembrolizumab + Carboplatin AUC
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American3
White27
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Olaparib + Pembrolizumab + Carboplatin AUC
United States30
08

Study locations

1 site
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2021 to primary completion in Oct 2025, 50 months.

Results were first posted in Oct 2026, 1 year after primary completion.

Of 299 non-industry phase 2 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 85. This study's 50 months is below that.

Counting every sponsor, half of 366 studies reached it within 53 months; a quarter within 35 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2020
First posted
Nov 25, 2020
StartActual
Aug 7, 2021
Primary completionActual
Oct 16, 2025
CompletionEst.
Oct 31, 2028
Results first posted
Oct 27, 2026
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 27, 2026
Eligibility
2 exclusion criteria edited
What changed in the criteria
Exclusion criteria
  • EditedHas received prior therapy with an anti-PD-1, andtianti-PD-L1, or anti PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX 40, CD137).
  • EditedFemale patients who are expecting to conceive or Mmalemale patients who are expecting to father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of trial treatment.
Oct 27, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedObjective response rateResponse Rate (ORR) as assessedAssessed by iRECISTRECIST v1.1Time frame: Through completion of treatment (estimated to be 2 years) → Through completion of follow-up (median length of follow-up 24.8 months, IQR=7.0-36.8 months)
Oct 27, 2026
Documents
Secondary outcomes
4 edited, 9 added, 3 removed
What changed in the outcomes
  • EditedDuration of responseResponse (DORDoR)Time frame: Through completion of treatment (estimated to be 2 years) → Through completion of follow-up (median length of follow-up 33.8 months, IQR=20.5-41.8 months)
  • EditedCorrelation of Baseline Tumor HR and PTEN Gene Status With Median Progression-free survival Free Survival (PFS)Time frame: Through completion of follow-up (estimated to be 3 years) → Through completion of follow-up (median length of follow-up 24.8 months, IQR=7.0-36.8 months)
  • EditedIncidence of adverse eventsAdverse EventsTime frame: Through 28 day follow-up (estimated to be 25 months) → Through 28 days after completion of treatment (median cycles (each cycle is 21 days) of treatment=10, IQR=3-26 cycles)
  • EditedOverall survivalProgression-free Survival (OSPFS)Time frame: Through completion of follow-up (estimated to be 3 years)
  • AddedCorrelation of Baseline Tumor HR and PTEN Gene Status With Objective Response Rate (ORR)Time frame: Through completion of follow-up (median length of follow-up 24.8 months, IQR=7.0-36.8 months)
  • AddedCorrelation of Baseline Tumor PD-L1 CPS Status With Objective Response Rate (ORR)Time frame: Through completion of follow-up (median length of follow-up 24.8 months, IQR=7.0-36.8 months)
  • AddedCorrelation of Baseline Tumor HPV (p16) Expression Status With Objective Response Rate (ORR)Time frame: Through completion of follow-up (median length of follow-up 24.8 months, IQR=7.0-36.8 months)
  • AddedCorrelation of Baseline Tumor PD-L1 CPS Status With Median Progression-free Survival (PFS)Time frame: Through completion of follow-up (median length of follow-up 24.8 months, IQR=7.0-36.8 months)
  • AddedCorrelation of Baseline Tumor HPV (p16) Expression Status With Median Progression-free Survival (PFS)Time frame: Through completion of follow-up (median length of follow-up 24.8 months, IQR=7.0-36.8 months)
  • AddedCorrelation of Baseline Tumor HR and PTEN Gene Status With Median Overall Survival (OS)Time frame: Through completion of follow-up (median length of follow-up 24.8 months, IQR=7.0-36.8 months)
  • AddedCorrelation of Baseline Tumor PD-L1 CPS Status With Median Overall Survival (OS)Time frame: Through completion of follow-up (median length of follow-up 24.8 months, IQR=7.0-36.8 months)
  • AddedCorrelation of Baseline Tumor HPV (p16) Expression Status With Median Overall Survival (OS)Time frame: Through completion of follow-up (median length of follow-up 24.8 months, IQR=7.0-36.8 months)
  • AddedOverall Survival (OS)Time frame: Through completion of follow-up (estimated to be 3 years)
  • RemovedHR and PTEN gene statusTime frame: Through completion of follow-up (estimated to be 3 years)
  • RemovedPD-L1 CPS statusTime frame: Through completion of follow-up (estimated to be 3 years)
  • RemovedHPV statusTime frame: Through completion of follow-up (estimated to be 3 years)
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Results posted
    Eligibility 2 exclusion criteria edited
    What changed in the criteria
    Exclusion criteria
    • EditedHas received prior therapy with an anti-PD-1, andtianti-PD-L1, or anti PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX 40, CD137).
    • EditedFemale patients who are expecting to conceive or Mmalemale patients who are expecting to father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of trial treatment.
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedObjective response rateResponse Rate (ORR) as assessedAssessed by iRECISTRECIST v1.1Time frame: Through completion of treatment (estimated to be 2 years) → Through completion of follow-up (median length of follow-up 24.8 months, IQR=7.0-36.8 months)
    Secondary outcomes 4 edited, 9 added, 3 removed
    What changed in the outcomes
    • EditedDuration of responseResponse (DORDoR)Time frame: Through completion of treatment (estimated to be 2 years) → Through completion of follow-up (median length of follow-up 33.8 months, IQR=20.5-41.8 months)
    • EditedCorrelation of Baseline Tumor HR and PTEN Gene Status With Median Progression-free survival Free Survival (PFS)Time frame: Through completion of follow-up (estimated to be 3 years) → Through completion of follow-up (median length of follow-up 24.8 months, IQR=7.0-36.8 months)
    • EditedIncidence of adverse eventsAdverse EventsTime frame: Through 28 day follow-up (estimated to be 25 months) → Through 28 days after completion of treatment (median cycles (each cycle is 21 days) of treatment=10, IQR=3-26 cycles)
    • EditedOverall survivalProgression-free Survival (OSPFS)Time frame: Through completion of follow-up (estimated to be 3 years)
    • AddedCorrelation of Baseline Tumor HR and PTEN Gene Status With Objective Response Rate (ORR)Time frame: Through completion of follow-up (median length of follow-up 24.8 months, IQR=7.0-36.8 months)
    • AddedCorrelation of Baseline Tumor PD-L1 CPS Status With Objective Response Rate (ORR)Time frame: Through completion of follow-up (median length of follow-up 24.8 months, IQR=7.0-36.8 months)
    • AddedCorrelation of Baseline Tumor HPV (p16) Expression Status With Objective Response Rate (ORR)Time frame: Through completion of follow-up (median length of follow-up 24.8 months, IQR=7.0-36.8 months)
    • AddedCorrelation of Baseline Tumor PD-L1 CPS Status With Median Progression-free Survival (PFS)Time frame: Through completion of follow-up (median length of follow-up 24.8 months, IQR=7.0-36.8 months)
    • AddedCorrelation of Baseline Tumor HPV (p16) Expression Status With Median Progression-free Survival (PFS)Time frame: Through completion of follow-up (median length of follow-up 24.8 months, IQR=7.0-36.8 months)
    • AddedCorrelation of Baseline Tumor HR and PTEN Gene Status With Median Overall Survival (OS)Time frame: Through completion of follow-up (median length of follow-up 24.8 months, IQR=7.0-36.8 months)
    • AddedCorrelation of Baseline Tumor PD-L1 CPS Status With Median Overall Survival (OS)Time frame: Through completion of follow-up (median length of follow-up 24.8 months, IQR=7.0-36.8 months)
    • AddedCorrelation of Baseline Tumor HPV (p16) Expression Status With Median Overall Survival (OS)Time frame: Through completion of follow-up (median length of follow-up 24.8 months, IQR=7.0-36.8 months)
    • AddedOverall Survival (OS)Time frame: Through completion of follow-up (estimated to be 3 years)
    • RemovedHR and PTEN gene statusTime frame: Through completion of follow-up (estimated to be 3 years)
    • RemovedPD-L1 CPS statusTime frame: Through completion of follow-up (estimated to be 3 years)
    • RemovedHPV statusTime frame: Through completion of follow-up (estimated to be 3 years)
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04643379
Collaborators
Merck Sharp & Dohme LLC, Joseph Sanchez Foundation
Responsible party
Sponsor
First posted
Nov 25, 2020
Start date
Aug 7, 2021
Primary completion
Oct 16, 2025
Completion
Oct 31, 2028 (estimated)
Results posted
Oct 27, 2026
Last update
Oct 27, 2026

Study contacts

Douglas Adkins, M.D.
principal investigator · Washington University School of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olaparib

Start the discussion